Insulet Corp.

Insulet Corp.

PODD
Insulet Corp.US flagNASDAQ
165.35
USD
-0.33
- -
11.45BMarket Cap
Insulet Corp.
PODD
(NASDAQ)

Recent

price

165.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.45
3.26
4.41
4.57
4.16
4.65
6.41
8
9.58
12.18
13.97
16.23
18.82
24.33
29.56
38.5
41.28
Revenue per Share
-1.54
-0.98
-1.08
-0.83
-0.93
-1.29
-0.5
-0.46
0.06
0.19
0.11
0.25
0.07
2.96
5.97
3.51
4.31
Basic EPS, GAAP
-1.06
-0.78
-0.84
-0.07
-0.05
-0.41
-0.11
-0.68
-2.23
1.51
0.72
-1.17
1.22
1.61
6.01
7.7
8.42
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.46
1.74
0.91
2.27
1.49
0.6
1.1
2.72
3.58
1.21
9.14
8.04
6.85
10.48
17.26
21.53
18.81
Book Value per Share
1.46
0.34
-0.34
1.26
0.57
-0.11
0.37
1.96
2.74
0.37
8.11
6.94
5.02
8.33
15.12
19.13
16.4
Tangible Book Value per Share
40
47
48
54
56
57
57
58
59
61
65
68
69
70
70
70
70
Basic Weighted Avg Shares
97
152
211
247
231
264
367
464
564
738
904
1,099
1,305
1,697
2,072
2,708
2,901
Sales/Revenue/Turnover
-35.27
-27.89
-17.02
-11.79
-3.84
-18.47
-2.92
-1.6
4.86
6.77
5.69
11.47
2.88
12.97
14.91
17.5
17.49
Operating Margin (%)
5
9
11
12
12
16
14
14
16
28
55
57
63
73
81
90
95
Depreciation Expense
-61
-46
-52
-45
-52
-74
-29
-27
3
12
7
17
5
206
418
247
303
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
36.54
20
29.9
18.05
53.06
3.87
- -
27.22
25.1
Effective Tax Rate (%)
-63.07
-30.1
-24.54
-18.2
-22.26
-27.86
-7.87
-5.78
0.59
1.57
0.75
1.53
0.35
12.16
20.19
9.12
10.44
Profit Margin (%)
124
105
62
156
164
126
314
451
346
433
1,041
1,101
949
1,132
1,363
1,234
1,022
Working Capital
69
109
104
119
166
172
333
566
592
888
1,044
1,249
1,374
1,366
1,296
931
930
LT Debt
66
83
44
125
84
34
63
159
212
76
604
556
476
733
1,212
1,515
1,303
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
2.27
4.52
2.75
5.91
0.95
10.52
- -
13.64
14.4
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
2.62
4.19
2.93
3.86
1.16
11.98
- -
11.48
13.32
Return on Capital (%)
-102.71
-61.53
-81.74
-53.3
-49.42
-124.74
-59.42
-24.18
1.78
8.06
2
2.9
0.89
34.12
43.03
18.12
23
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
80
18
19
LT Borrowings
935
931
930
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
70
70
69
Market Capitalization
21,718
20,008
14,534

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,859
1,914
1,710
Cash, Cash Equivalents & STI
758
716
480
Accounts Receivable, Net
453
511
542
Inventories
446
453
462
Total Current Liabilities
648
680
688
Payables & Accruals
395
339
419
ST Debt
80
18
19
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
102.34%
24.41%
25.07%
Free Cash Flow
33.64%
-28.03%
28.59%
Net Income, GAAP
455.1%
904.21%
-40.93%
Sales/Revenue/Turnover
26.36%
24.62%
30.73%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
442
488
544
598
2,072
2025
569
649
706
784
2,708
2026
762
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.74
2.69
1.11
1.44
5.97
2025
0.5
0.32
1.24
1.44
3.51
2026
1.3
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Insulet Corporation (NASDAQ: PODD) is a medical device company that designs, develops, manufactures and commercializes innovative tubeless insulin delivery systems and related products primarily for people with diabetes; its flagship Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors for automated insulin dosing via a smartphone app or dedicated controller, the Omnipod DASH Insulin Management System featuring Bluetooth-enabled touchscreen control and waterproof tubeless Pods delivering continuous insulin for up to 72 hours without needles, the Omnipod GO pre-filled disposable Pod system for type 2 diabetes patients requiring basal insulin, and the core Omnipod Insulin Management System offering wearable needle-free delivery; the company also pursues applications of its Pod technology for non-insulin subcutaneous drug delivery in other therapeutic areas through its Drug Delivery segment. Headquartered in Acton, Massachusetts, and founded in 2000, Insulet operates highly automated manufacturing facilities with key geographic presence in the US, Europe, Asia Pacific, the Middle East, Australia and select emerging markets including China and Malaysia, serving approximately 500,000 global customers across 25 countries. In recent developments, the company completed acquisitions of automated insulin delivery assets from Bigfoot Biomedical and Automated Glucose Control LLC for $25 million each to bolster its Omnipod 5 technology, announced a proposed $450 million senior unsecured notes offering due 2033 and amendments to its credit agreement extending revolving credit facility maturity to 2030 with commitments increased to $500 million to redeem its 0.375% Convertible Senior Notes due 2026 including the remaining $380 million principal, integrated Omnipod 5 with Dexcom G7 in multiple European markets alongside new CGM reimbursements in Norway, extended its supply agreement with NXP USA effective 2025 for critical manufacturing components, redeemed outstanding convertible notes, and raised its fiscal 2025 revenue growth guidance to 28-29% at constant currency while outlining a long-term strategy targeting 20% revenue CAGR through 2028 driven by global expansion, operational efficiencies and innovation.

Company News

APIChatGPT
  • ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD

  • ROSEN, SKILLED INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - PODD

  • Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm

  • PODD INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026

  • The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 31, 2026 in Insulet Corporation Lawsuit - PODD

  • The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 31, 2026 in Insulet Corporation Lawsuit - PODD

  • $PODD Securities: Suffer Losses on Your Insulet Investment? BFA Law Reminds Investors of the Securities Fraud Lawsuit to Recover Losses

  • Insulet Corporation Investor Alert: Contact SBS by August 31, 2026 for Opportunity to Lead Securities Fraud Lawsuit

  • Insulet Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PODD

  • ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - PODD

  • Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

  • Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm

  • Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

  • PODD Shareholder Alert: Insulet Corporation Securities Class Action Lawsuit - Investors Should Contact SueWallSt

  • ROSEN, A RANKED AND LEADING FIRM, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD

  • ROSEN, A RANKED AND LEADING FIRM, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD

  • Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm

  • PODD DEADLINE: Levi & Korsinsky Reminds Insulet Corporation Investors of Upcoming Securities Class Action Deadline

  • INSULET CORPORATION INVESTORS WITH LOSSES HAVE UNTIL AUGUST 31, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

  • PODD UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026